Cite
HARVARD Citation
Kim, D. et al. (2021). Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. British journal of haematology. pp. 779-791. [Online].